Prostate Cancer International is
for 2011 by Great NonProfits
Today’s news reports contain items on: Racial disparities in 10-year survival, even in specialized clinical trials Sunitinib + docetaxel in treatment of CRPC Docetaxel + ABT-751 in treatment of CRPC
Filed under: Drugs in development, Management, Treatment, Uncategorized | Tagged: ABT-751, docetaxel, racial disparities, sunitinib, survival | Leave a Comment »
In today’s news reports we cover items on: Prediction of risk for prostate cancer under-grading based on biopsy data The obesity/risk equation in prostate cancer Capecitabine + docetaxel in metastatic CRPC
Filed under: Diagnosis, Drugs in development, Management, Risk, Treatment | Tagged: biopsy, capecitabine, CRPC, docetaxel, Gleason score, obesity, risk, under-grading | Leave a Comment »
Today’s prostate cancer news reports address: A review of data on the potential for prostate cancer prevention A review of appropriate strategic options for rebiopsy in patients at risk Prostate cancer in men with a PSA < 2.5 ng/ml The sequential use of multiple cycles of docetaxel therapy
Filed under: Diagnosis, Management, Prevention, Risk, Treatment | Tagged: docetaxel, low PSA, Prevention, rebiopsy, risk, sequential | Leave a Comment »
Today’s news reports cover such items as: Identification of prostate cancer cells in urine Prognosis after radiation therapy The effect of bisphenol A on prostate cancer therapy The appropriateness of primary androgen deprivation for localized prostate cancer Data from clinical trials of Phase II clinical trial of docetaxel + samarium-153 lexidronam and cyclophosphamide + dexamethasone [...]
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: ADT, androgen deprivation therapy, bisphenol A, cyclophosphamide, Diagnosis, docetaxel, primary, prognosis, risk, samarium-153 | Leave a Comment »
In today’s news reports there are items on: Genetic modifications and prostate cancer risk and development Situation-specific prostate biopsy strategies A viral vector-prodrug combination in treatment of local and locally advanced disease Docetaxel + 153Sm lexidronam in metastatic CRPC
Filed under: Diagnosis, Drugs in development, Management, Risk | Tagged: biopsy, CB1954, development, docetaxel, gene, risk, samarium-153 lexidronam, vector | Leave a Comment »
In today’s new items we identified items dealing with: New learnings about radical prostatectomy Heated gold nanoparticles as treatment for solid tumors A three-drug chemotherapy combination for HRPC
Filed under: Drugs in development, Management, Treatment | Tagged: docetaxel, estramustine, gold, HRPC, nanoparticles, radical prostatectomy, vinorelbine | Leave a Comment »
In today’s other news reports there are items on: Mistrust between patients and their doctors regarding prostate cancer issues Use of a new, 3D transrectal ultrasound-guided biopsy system Pelvic lymph node dissection and its extent in prostate cancer staging and outcome Negative result of oblimersen sodium prior to docetaxel in castration-resistant prostate cancer
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: biopsy, docetaxel, mistrust, oblimersen, pelvic lymph node dissection, PLND, three-dimensional, transrectal, ultrasound-guided | Leave a Comment »
A media release hyping a new report from the market research firm Decision Resources states that “surveyed oncologists identify a therapy’s effect on overall survival as the attribute that most influences their prescribing decisions in stage III prostate cancer” and goes on to say that “the opinions of interviewed thought leaders indicate that Sanofi-Aventis’s Taxotere [...]
Filed under: Drugs in development, Management, Treatment | Tagged: docetaxel, Stage III | 1 Comment »
Today’s news includes information on: The use of markers for prognosis following first-line treatment for localized prostate cancer Results of a Phase II trial of neoadjuvant docetaxel + gefitinib prior to radical prostatectomy Results of a Phase III trial of gabapentin in management of ADT-related “hot flashes” MRI-directed HIFU in the treatment of localized prostate [...]
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: docetaxel, doubling time, gabapentin, gefitinib, HIFU, hot flashes, PSA velocity | Leave a Comment »
With at least a dozen new reports available today, we have chosen to focus only on the most significant, several of which may be of clinical importance now or in the near future. Most of the other items provide minimal new information and can be accessed through the UroToday web site by those who are interested.
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: BMI, body mass index, dexamethasone, docetaxel, genetic testing, genetics, laparoscopic surgery, LRP, prior malignancies, RALP | Leave a Comment »
Today’s reports cover such items as: Disparities in cancer mortality between blacks and whites in the USA Body mass, body fat distribution, and risk for prostate cancer Risk for cancer in male carriers of BRCA mutations A five-SNP genetic marker set and prostate cancer risk Final results of the atrasentan trial in non-metastatic, HRPC patients [...]
Filed under: Drugs in development, Management, Prevention, Treatment | Tagged: atrasentan, BMI, BRCA mutation, disparity, docetaxel, fat distribution, genetic marker, PGDF, SNP | Leave a Comment »
Two reports just published would appear to confirm individual patient experiences in the treatment of advanced disease: The impact of ADT on body composition The effects of docetaxel chemotherapy in men aged ≥ 75 years
Filed under: Management, Treatment | Tagged: androgen, cancer, chemotherapy, deprivation, docetaxel, news, prostate, update | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site